Nina Herne
CEO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 (0) 70-7147457
Email: nina.herne@liddspharma.se
Anja Peters
CFO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 733 260000
Email: anja.peters@liddspharma.com
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
KALLELSE TILL ÅRSSTÄMMA I LIDDS AB (publ)- 2021-04-16
Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology® - 2021-04-08 International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules
- 2021-03-31 LIDDS CEO Interview with Finwire TV and Updated Company Presentation
- 2021-03-30 LIDDS updates on the Clinical Program for Liproca Depot
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
